Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10316
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDamianovich, Den
dc.contributor.authorAdena, Men
dc.contributor.authorTebbutt, Niall Cen
dc.date.accessioned2015-05-15T23:43:54Z
dc.date.available2015-05-15T23:43:54Z
dc.date.issued2007-02-06en
dc.identifier.citationBritish Journal of Cancer 2007; 96(4): 546-50en
dc.identifier.govdoc17285136en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10316en
dc.description.abstractRandomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC). However, patients enrolled in clinical studies represent a restricted population and little is known about the use of O and I in the general population and the subsequent outcomes outside clinical studies. We used the Australian Health Insurance Commission (HIC) database to describe prescribing patterns of O and I and their impact on survival in all patients with 5-fluorouracil (5-FU) refractory CRC in Australia in 2002 and 2003. In 2999 patients, there was a marked increase in initial treatment with O rather than I; 48% of patients received O first in 2002 vs 66% in 2003 (P<0.001). Overall 40-45% of patients received both O and I; however, younger patients were more likely to receive both drugs (P<0.001). After 5-FU failure and treatment with O or I, the proportion of patients surviving 6 or 12 months was estimated to be 0.67 (95% CI, 0.66-0.69) and 0.42 (95% CI, 0.40-0.44), respectively. Survival was superior for patients who received both O and I; however, the sequence of agents had no impact. Older patients (> or =70 years) had inferior survival no matter which drug was used as initial treatment. Analysis of the Australian HIC database provides a valuable means of assessing patterns of use and outcomes of new therapies.en
dc.language.isoenen
dc.subject.otherAge Distributionen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic useen
dc.subject.otherAustralia.epidemiologyen
dc.subject.otherCamptothecin.administration & dosage.adverse effects.analogs & derivativesen
dc.subject.otherCohort Studiesen
dc.subject.otherColorectal Neoplasms.drug therapy.mortality.secondaryen
dc.subject.otherDatabases, Factualen
dc.subject.otherDisease Progressionen
dc.subject.otherDrug Resistance, Neoplasmen
dc.subject.otherDrug Utilization.trendsen
dc.subject.otherFemaleen
dc.subject.otherFluorouracil.adverse effects.therapeutic useen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherNational Health Programs.statistics & numerical dataen
dc.subject.otherOrganoplatinum Compounds.administration & dosage.adverse effectsen
dc.subject.otherOutcome Assessment (Health Care).statistics & numerical dataen
dc.subject.otherPhysician's Practice Patterns.trendsen
dc.subject.otherPrognosisen
dc.subject.otherRandomized Controlled Trials as Topic.statistics & numerical dataen
dc.subject.otherRecurrenceen
dc.subject.otherSex Distributionen
dc.subject.otherSurvival Analysisen
dc.titleTreatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish Journal of Canceren
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1038/sj.bjc.6603590en
dc.description.pages546-50en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17285136en
dc.type.austinJournal Articleen
local.name.researcherTebbutt, Niall C
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.